Clin Lab. 2021 Apr 1;67(4). doi: 10.7754/Clin.Lab.2020.200828.
To investigate the clinical value of serum concentration of carcinoembryonic antigen (CEA), carbohydrate antigen 24-2 (CA24-2), and carbohydrate antigen 19-9 (CA19-9) in the detection of colorectal cancer (CRC).
The serum levels of tumor markers and KRAS/NRAS/PIK3CA/BRAF gene mutations were detected in patients with colorectal cancer. Clinical medical records in colorectal cancer patients were collected.
A total of 2,281 patients were recruited in the study, included 1,578 colorectal cancer patients and 703 controls. CEA, CA24-2, and CA19-9 concentrations were significantly higher in the colorectal cancer group than in the control group. The sensitivity of these tumor markers sorted in descending order was CEA>CA19-9>CA24-2. The best specificity was CA24-2, followed by CA19-9 and CEA, with all were more than 92%. The combination of CEA, CA19-9, and CA24-2 ranked the best sensitivity and specificity for colorectal cancer diagnosis. The prediction equation excluding the risk of colorectal cancer was. Probability (normal) = Exp (-5.47 - 0.28CEA - 0.11CA242 + 0.001CA199)/(1+ Exp (-5.47 - 0.28CEA - 0.11CA242 + 0.001CA199)). Besides, there were no significant differences in age, gender, histology type, differentiation, depth of invasion, and TNM stage in KRAS/ NRAS, BRAF, and PIK3CA mutations compared with wild type.
Serum CEA, CA24-2, and CA19-9 are valuable indicators for predicting the risk of colorectal cancer.
探讨癌胚抗原（CEA）、糖类抗原 24-2（CA24-2）和糖类抗原 19-9（CA19-9）血清浓度在结直肠癌（CRC）检测中的临床价值。
检测结直肠癌患者的肿瘤标志物血清水平和 KRAS/NRAS/PIK3CA/BRAF 基因突变。收集结直肠癌患者的临床病历资料。
共纳入 2281 例患者，其中结直肠癌患者 1578 例，对照组 703 例。结直肠癌组患者 CEA、CA24-2 和 CA19-9 浓度均明显高于对照组。这些肿瘤标志物的灵敏度依次为 CEA>CA19-9>CA24-2。最佳特异性为 CA24-2，其次是 CA19-9 和 CEA，均大于 92%。CEA、CA19-9 和 CA24-2 联合用于结直肠癌诊断的敏感性和特异性最佳。排除结直肠癌风险的预测方程为。概率（正常）=Exp（-5.47-0.28CEA-0.11CA242+0.001CA199）/（1+Exp（-5.47-0.28CEA-0.11CA242+0.001CA199））。此外，KRAS/NRAS、BRAF 和 PIK3CA 突变与野生型相比，在年龄、性别、组织学类型、分化程度、浸润深度和 TNM 分期方面无显著差异。
血清 CEA、CA24-2 和 CA19-9 是预测结直肠癌风险的有价值指标。
